STOCK TITAN

Alpha Cognition Inc - ACOGF STOCK NEWS

Welcome to our dedicated news page for Alpha Cognition (Ticker: ACOGF), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alpha Cognition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alpha Cognition's position in the market.

Rhea-AI Summary
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) announces participation in the Emerging Growth Conference on April 3, 2024, presenting its lead asset, ALPHA-1062 for Alzheimer's disease. Investors can interact with the CEO and COO during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
conferences
-
Rhea-AI Summary
Alpha Cognition Inc. announces the filing of a new composition-of-matter patent for its lead asset, ALPHA-1062, aimed at treating mild-to-moderate Alzheimer's Disease. The patent, if approved, will secure protection for the oral formulation of ALPHA-1062 until 2044, enhancing the company's existing patent protection until 2042.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
none
-
News
Rhea-AI Summary
Alpha Cognition Inc. provides a business update on its ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer’s disease, highlighting its commercialization strategy, and pipeline expansion. The company aims to launch ALPHA-1062 into the large U.S. Alzheimer’s market, targeting improved outcomes for patients and addressing physician dissatisfaction with current therapies. With a PDUFA date set for July 27, 2024, if approved, ALPHA-1062 could be a significant addition to Alzheimer’s treatment options, potentially transforming the company's position in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
Rhea-AI Summary
Alpha Cognition Inc. has completed a final closing for its private placement, issuing 16,965,762 units at a price of US$0.22 per unit for gross proceeds of US$3,732,467. The Company expects to use the net proceeds for research and development, general and administrative matters, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) has completed a fourth closing of its private placement, issuing 9,141,534 units at a price of US$0.22 per unit for gross proceeds of US$2,011,138. The company has received gross proceeds of US$4.7 million to date and is continuing the offering for up to an additional US$1.8 million. The net proceeds will be used for research and development, general and administrative matters, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Alpha Cognition Inc. (ACOG) announces FDA acceptance of New Drug Application (NDA) for ALPHA-1062, a treatment for mild-to-moderate Alzheimer’s Disease. PDUFA goal date set for July 27th, 2024. Adverse events for ALPHA-1062 were less than 2% with no observed insomnia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
102.03%
Tags
clinical trial
Rhea-AI Summary
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) has amended the terms of its private placement offering, raising US$2.7 million and expecting an additional US$3.8 million. Each unit now consists of one common share and one share purchase warrant. The company plans to use the net proceeds for research and development, general and administrative matters, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Alpha Cognition Inc. (ACOG) reported financial results for the third quarter and nine months ended September 30, 2023, including the submission of the New Drug Application to the FDA for ALPHA-1062, a proprietary tablet formulation for Alzheimer's disease. The company also received an issued patent for ALPHA-1062, awarded a $750,000 R&D grant, and announced a private placement offering. Additionally, the company initiated work to out-license ALPHA-1062IN for traumatic brain injury applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.38%
Tags
none
-
Rhea-AI Summary
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) completes third closing of private placement, issuing 4,590,903 units at US$0.22 per unit for gross proceeds of US$1,009,999. Gross proceeds to date are US$2.7 million, with an additional offering of up to US$3.8 million. Net proceeds will be used for research and development, general and administrative matters, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11%
Tags
none
Rhea-AI Summary
Alpha Cognition completes second closing of private placement, raising $351,303
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.1%
Tags
none
Alpha Cognition Inc

OTC:ACOGF

ACOGF Rankings

ACOGF Stock Data

67.90M
90.51M
11.95%
6.33%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Vancouver